Join Now

Category Archives: BioUtah News

Peer-Reviewed Article Reporting DiscGenics’ Cell Therapy Phase I/II Study Results Receives International Journal of Spine Surgery Best Paper Award

Salt Lake City, UT – April 9, 2025 – DiscGenics, Inc., a privately held, late-stage clinical, biopharmaceutical company developing allogeneic, cell-based, regenerative therapies for musculoskeletal degeneration, today announced that the double-blind, peer-reviewed article, “Allogeneic Disc Progenitor Cells Safely Increase Disc Volume and Improve Pain, Disability, and Quality of Life in Patients With Lumbar Disc Degeneration—Results […]

| Comments Off on Peer-Reviewed Article Reporting DiscGenics’ Cell Therapy Phase I/II Study Results Receives International Journal of Spine Surgery Best Paper Award

BREAKING GROUND ON COMPREHENSIVE CANCER CENTER IN VINEYARD

Huntsman Cancer Institute at the University of Utah (the U) broke ground on its second Comprehensive Cancer Center on Tuesday, April 8, advancing construction of a new facility wholly dedicated to delivering prevention, hope, and healing to cancer patients. Situated in Vineyard, in the heart of Utah County, the Huntsman Cancer Institute site will reduce […]

| Comments Off on BREAKING GROUND ON COMPREHENSIVE CANCER CENTER IN VINEYARD

The ‘Father of Modern Food and Drug Law,’ Peter Hutt, Joins EVŌQ Nano Board of Directors

Hutt Brings Decades of Regulatory Insight to Help Advance Nanoparticle Technology Platform  SALT LAKE CITY, Utah (April 9, 2025) — EVŌQ Nano, a nanoscience company that engineers novel nanoparticles for the life, material, and textile science industries, today announced the appointment of Peter Barton Hutt, former FDA Chief Counsel, to its board of directors. Widely […]

| Comments Off on The ‘Father of Modern Food and Drug Law,’ Peter Hutt, Joins EVŌQ Nano Board of Directors

Recursion and Enamine Release New AI-Enabled Targeted Compound Libraries

Kyiv, Ukraine and Salt Lake City, UT, April 09, 2025 (GLOBE NEWSWIRE) — Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced the generation of screening libraries leveraging tools within its AI/ML platform, the Recursion OS, with Enamine’s REAL Space, the world’s largest source of make-on-demand small […]

| Comments Off on Recursion and Enamine Release New AI-Enabled Targeted Compound Libraries

Recursion Announces First Patient Dosed in Phase 1 Clinical Study of REC-3565, a Selective MALT1 Inhibitor for Relapsed or Refractory B-cell Lymphomas

REC-3565 is a potential best-in-class MALT1 inhibitor for multiple hematology indications, designed to reduce the risk of hyperbilirubinemia, a common side effect of other MALT1 inhibitorsSalt Lake City, UT, April 08, 2025 (GLOBE NEWSWIRE) — Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced that the first patient has […]

| Comments Off on Recursion Announces First Patient Dosed in Phase 1 Clinical Study of REC-3565, a Selective MALT1 Inhibitor for Relapsed or Refractory B-cell Lymphomas

Merit Medical Launches the Ventrax™ Delivery System

Novel all-in-one retrograde aortic access delivery system supports streamlined treatment of ventricular tachycardia SOUTH JORDAN, Utah, April 09, 2025 (GLOBE NEWSWIRE) — Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader in healthcare technology, today announced the US commercial release of its Ventrax Delivery System. The new delivery system is Merit’s latest addition to its growing […]

| Comments Off on Merit Medical Launches the Ventrax™ Delivery System

PhotoPharmics Reaches 200 Participants in Landmark Light for PD Clinical Trial

Two-thirds enrolled in one of the largest remote Parkinson’s trials—redefining access and inclusion in therapeutic research Salt Lake City, Utah – PhotoPharmics announced today that its Pivotal, Phase 3 clinical trial, Light for PD™, has now reached 200 participants—marking two-thirds of its target enrollment. This milestone positions the study as one of the largest remote […]

| Comments Off on PhotoPharmics Reaches 200 Participants in Landmark Light for PD Clinical Trial

G2G Consulting Provides Updates from Washington D.C.

G2G Consulting Provides Updates from Washington D.C.

| Tagged | Comments Off on G2G Consulting Provides Updates from Washington D.C.

Ribbon Cutting Ceremony for New Denali Facility in Salt Lake City

BioUtah member, Denali Therapeutics, yesterday celebrated the grand opening of its new state-of-the-art manufacturing facility in Salt Lake City. Denali is using deep scientific and drug development expertise to discover and deliver effective biologic therapeutics to the brain. Co-founder and CEO, Ryan Watts, addressed the crowd who gathered to share the milestone with colleagues, public […]

| Comments Off on Ribbon Cutting Ceremony for New Denali Facility in Salt Lake City

bioMérieux Recognized as Top 1% by S&P Global

bioMérieux Recognized as Top 1% by S&P Global

| Tagged | Comments Off on bioMérieux Recognized as Top 1% by S&P Global

Merit Medical Releases 12-Month Efficacy Results of the WRAPSODY® Cell-Impermeable Endoprosthesis (CIE)

Merit Medical Releases 12-Month Efficacy Results of the WRAPSODY® Cell-Impermeable Endoprosthesis (CIE)

| Tagged | Comments Off on Merit Medical Releases 12-Month Efficacy Results of the WRAPSODY® Cell-Impermeable Endoprosthesis (CIE)

bioMérieux receives FDA 510(k) Clearance for its VITEK® COMPACT PRO

Marcy l’Étoile, France, March 18th, 2025 – bioMérieux, a world leader in the field of in vitro diagnostics, announces the U.S. Food and Drug Administration (FDA) 510(k) clearance for VITEK® COMPACT PRO. This innovative system for microorganism identification (ID) and antibiotic susceptibility testing (AST) will benefit clinical laboratories to help diagnose infectious diseases and combat […]

| Comments Off on bioMérieux receives FDA 510(k) Clearance for its VITEK® COMPACT PRO